|Day Low/High||14.92 / 16.17|
|52 Wk Low/High||1.30 / 4.17|
Investors considering a purchase of Arena Pharmaceuticals Inc shares, but tentative about paying the going market price of $1.35/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $1 strike, which has a bid at the time of this writing of 27 cents.
- Lewis Rubin, M.D. and Vallerie McLaughlin, M.D. to Present
Pacific Biosciences of California, Alexion Pharmaceuticals and Arena Pharmaceuticals were among the biotech stock movers in premarket trading on Thursday.
Arena Pharmaceuticals, Rigel Pharmaceuticals and Cytokinetics were among the biotech stock movers in premarket trading on Tuesday.
- Data to highlight etrasimod, Arena's orally available next generation sphingosine-1-phosphate (S1P) receptor modulator for the potential treatment of autoimmune diseases -
Here's how to trade six of the most active names on the market today.
Arena Pharmaceuticals, Immunomedics and Aralez Pharmaceuticals were among the biotech stock movers in premarket trading on Wednesday.
Investors in Arena Pharmaceuticals Inc saw new options become available this week, for the October 20th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Arena Expects to Receive $23 Million of Cash Payments and Over $80 Million of Potential Cost Relief and Will Continue to Focus on Its Clinical Programs